A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

NCT00516373 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
BRCA1 Protein
BRCA2 Protein

Interventions

DRUG: KU-0059436 (AZD2281)(PARP inhibitor)

Sponsor

AstraZeneca